Viral growth inhibition
AssigneeRibotargets, Ltd.
InventorsJonathan Karn, Michael John Gait, Shaun Heaphy, Colin Dingwall
Life of this patent
Estimating the term…
Abstract
A synthetic molecule comprises at least one oligonucleotide comprising an RNA binding sequence or sequences corresponding to the site bound by the HIV protein rev and capable of binding ot rev within cells. The binding sequence or sequences, by binding with rev within cells, can act to cause inhibition of growth of any HIV present in the cells, and so has potential therapeutic use in treatment of patients infected with HIV. The invention also provides an assay for identifying that inhibit rev binding.
Claims12
An assay for identifying a compound that inhibits the binding of HIV Rev to HIV RRE, comprising
- contacting a candidate compound with Rev in the presence of an oligonucleotide that binds to HIV Rev protein with an affinity of no more than 8 nM, wherein the sequence of said oligonucleotide is not found in wild type RRE, and wherein said oligonucleotide comprises a purine-rich bubble containing Watson-Crick base-paired and non-base-paired nucleotides;
- and
- determining the degree of binding of Rev to said oligonucleotide relative to the binding in the absence of said candidate compound.
An assay for identifying a compound that inhibits the binding of HIV Rev to HIV RRE, comprising
- contacting a candidate compound with Rev in the presence of an oligonucleotide that binds to HIV Rev protein, said oligonucleotide comprising a purine-rich bubble containing Watson-Crick base-paired and non-base-paired nucleotides and said oligonucleotide comprising at least one base pair adjacent to said bubble and not found in wild type RRE, on at least one side of said bubble;
- and
- determining the degree of binding of Rev to said oligonucleotide relative to the binding in the absence of said candidate compound.
An assay for identifying a compound that inhibits the binding of HIV Rev to HIV RRE, comprising contacting a candidate compound with Rev in the presence of a first oligonucleotide and a second oligonucleotide, wherein said first and second oligonucleotides form a duplex that binds to HIV Rev protein with an affinity of no more than 8 nM, and said duplex comprises a purine-rich bubble containing Watson-Crick base-paired and non-base-paired nucleotides;
- and
- determining the degree of binding of Rev to said annealed first oligonucleotide and second oligonucleotide relative to the binding in the absence of said candidate compound.
An assay for identifying a compound that inhibits the binding of HIV Rev to HIV RRE, comprising
- contacting a candidate compound with Rev in the presence of a first oligonucleotide and a second oligonucleotide, wherein said first and second oligonucleotides form a duplex that binds to HIV Rev protein and comprises a purine-rich bubble containing Watson-Crick base-paired and non-base-paired nucleotides and said duplex comprises at least one base pair adjacent to said bubble and not found in wild type RRE, on at least one side of said bubble;
- and
- determining the degree of binding of Rev to said annealed first oligonucleotide and second oligonucleotide relative to the binding in the absence of said candidate compound.
Dependencies are inferred from the claim text.